A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination with Carboplatin in Patients with Advanced HER-2 Negative Breast Cancer

Trial Identifier: D081EC00001
Sponsor: AstraZeneca
NCTID:: NCT02561832
Start Date: November 2015
Primary Completion Date: September 2016
Study Completion Date: February 2017
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Israel Beersheva, Israel, IL-84101
Israel Kfar-Saba, Israel, 4428164
Israel Tel-Aviv, Israel, 64239
Spain Barcelona, Spain, 08035
Spain Lérida, Spain, 25198
Spain Madrid, Spain, 28034
Spain Madrid, Spain, 28050
Spain Valencia, Spain, 46010
Spain Zaragoza, Spain, 50009
United States of America, CA Los Angeles, CA, United States of America, 90048
United States of America, FL Ft Myers, FL, United States of America, 33905
United States of America, NY New York, NY, United States of America, 10065
United States of America, NY Stony Brook, NY, United States of America, 11794
United States of America, TN Memphis, TN, United States of America, 38120